|Articles|September 1, 1996

September 1996
Volume 2
Issue 8

Potential for SSRIs as Monotherapy for Comorbid Psychiatric Disorders

Download PDF: Potential for SSRIs as Monotherapy for Comorbid Psychiatric Disorders

Articles in this issue

about 30 years ago

Article

Determinants of Hospital Charges and Costs in Acute Myocardial Infarction: A Report from the Myocardial Infarction Cost Study (MICS) Group

about 30 years ago

Article

The Effectiveness of Postgraduate Education on the Clinical Breast Examination Skills of Primary Care Physicians

about 30 years ago

Article

Treatment Outcome in an Outpatient Asthma Center: Retrospective Questionnaire Data

about 30 years ago

Article

Potential Cost-Effectiveness of Acute Stroke Treatment

about 30 years ago

Article

Effect of a Comprehensive Nurse-Managed Diabetes Program: An HMO Prospective Study

about 30 years ago

Article

The Economic Organization of Health Resource Allocation: Decision Making in the New Environment

about 30 years ago

Article

Pharmacoeconomic Evaluation of HMG-CoA Reductase Inhibitors in the Treatment of Hypercholestrolemia

about 30 years ago

Article

Establishing the Basis for Successful Disease Management Contracting

about 30 years ago

Article

Accreditation Standards in Managed Care

about 30 years ago

Article

A Closer Look at Capitation

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Content

Predicting GLP-1 Discontinuation From Pharmacy Claims

ByAayush Sisodia, MSHI, BDS

Published: August 6th 2026 | Updated: August 31st 2026

Impact of Automated Insulin Delivery on Type 2 Diabetes Measures

ByThomas W. Martens, MD,Bimal V. Patel, PharmD, MS,Sharon M. Wang, PharmD, MS,Laurel H. Messer, PhD, MPH, RN, CDCES, BC-ADM,Jordan E. Pinsker, MD,Daniel C. Malone, PhD, RPh,Miranda R. Polin, MS, BS,Diana I. Brixner, PhD, RPh,Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES,Osagie Ebekozien, MD, MPH

July 23rd 2026

Geographical Access to Preferred Pharmacies in Medicare Part D

ByPinka Chatterji, PhD,Yiran Han, PhD,Chun-Yu Ho, PhD

July 22nd 2026

Roles and Priorities Guiding Medicare Advantage Postacute Home Health Referrals

ByEmily A. Gadbois, PhD,Jennifer Bunker, MPH,Marguerite Daus, PhD, RN,Jamie M. Smith, PhD, RN,Emily Buss, MSN, RN,Christine D. Jones, MD, MS,Kali S. Thomas, PhD, MA

July 16th 2026

Reply to Letter Regarding “Preventive Dental Care and Overall Medical Expenditures”

ByHeather L. Taylor, MPH, LDH,Ann M. Holmes, PhD,Nir Menachemi, PhD, MPH,Justin Blackburn, PhD

July 10th 2026

Potential for SSRIs as Monotherapy for Comorbid Psychiatric Disorders

Articles in this issue

Related Content

Predicting GLP-1 Discontinuation From Pharmacy Claims

Impact of Automated Insulin Delivery on Type 2 Diabetes Measures

Geographical Access to Preferred Pharmacies in Medicare Part D

Roles and Priorities Guiding Medicare Advantage Postacute Home Health Referrals

Reply to Letter Regarding “Preventive Dental Care and Overall Medical Expenditures”

Trending on AJMC

Newer Agents, New Advantages: Brexpiprazole, Cariprazine, and Lumateperone in MDD

5 August FDA Approvals Marked by Novelty, Pushback

Dosing, Tolerability, and Formulary Impact: Aripiprazole and Quetiapine XR in MDD

Cross-Trial Vitiligo Data: What Payers Can and Can't Compare

Counseling Vitiligo Patients on Time to Repigmentation